Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

The drug pazopanib (Votrient) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended ...

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Bone cancer represents a serious medical condition that affects thousands of people each year, yet many individuals remain unfamiliar with its characteristics, symptoms, and treatment approaches.

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...

A combination of genetic tests for a "very complex" blood cancer could accurately predict if the disease is likely to return ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...